MENU
+Compare
TARS
Stock ticker: NASDAQ
AS OF
Sep 26, 10:41 AM (EDT)
Price
$55.98
Change
+$0.60 (+1.08%)
Capitalization
2.34B

TARS Tarsus Pharmaceuticals Forecast, Technical & Fundamental Analysis

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care... Show more

TARS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for TARS with price predictions
Sep 25, 2025

TARS's RSI Indicator ascending out of oversold territory

The RSI Oscillator for TARS moved out of oversold territory on September 16, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In of the 22 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 24, 2025. You may want to consider a long position or call options on TARS as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for TARS moved above the 200-day moving average on September 11, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TARS advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .

TARS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 215 cases where TARS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Moving Average Convergence Divergence Histogram (MACD) for TARS turned negative on September 04, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TARS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TARS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.032) is normal, around the industry mean (19.714). P/E Ratio (0.000) is within average values for comparable stocks, (54.201). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.145). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (7.457) is also within normal values, averaging (346.197).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TARS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
TARS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

TARS is expected to report earnings to fall 24.06% to -36 cents per share on November 05

Tarsus Pharmaceuticals TARS Stock Earnings Reports
Q3'25
Est.
$-0.36
Q2'25
Missed
by $0.10
Q1'25
Beat
by $0.15
Q4'24
Beat
by $0.17
Q3'24
Beat
by $0.33
The last earnings report on August 06 showed earnings per share of -47 cents, missing the estimate of -37 cents. With 5.32K shares outstanding, the current market capitalization sits at 2.34B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
15440 Laguna Canyon Road
Phone
+1 949 409-9820
Employees
244
Web
https://www.tarsusrx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WEBAX10.61N/A
N/A
TETON Westwood Balanced AAA
LMPOX35.81N/A
N/A
ClearBridge Small Cap Growth R
COFRX41.28N/A
N/A
Columbia Contrarian Core Inst2
FSERX17.28N/A
N/A
Franklin Real Estate Securities R6
EISVX29.83N/A
N/A
Carillon ClariVest Intl Stock R6

TARS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, TARS has been loosely correlated with XERS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if TARS jumps, then XERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TARS
1D Price
Change %
TARS100%
+0.24%
XERS - TARS
39%
Loosely correlated
-1.88%
RYTM - TARS
39%
Loosely correlated
+2.30%
ERAS - TARS
38%
Loosely correlated
-5.24%
CRNX - TARS
38%
Loosely correlated
+2.02%
OCUL - TARS
37%
Loosely correlated
-2.55%
More